Prosecution Insights
Last updated: April 19, 2026

Magenta Therapeutics Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17507456 CONDITIONING METHODS FOR GENE THERAPY PETERS, ALEC JON 1641 Final Rejection Oct 21, 2021
17368815 USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY HOLTZMAN, KATHERINE ANN 1646 Final Rejection Jul 06, 2021
16863948 FC SILENCED ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ADCS) BRISTOL, LYNN ANNE 1643 Non-Final OA Apr 30, 2020

Managing Magenta Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month